https://doi.org/10.4081/monaldi.2023.2737
Comments on “Post-extubation high-flow nasal cannula oxygen therapy versus non-invasive ventilation in chronic obstructive pulmonary disease with hypercapnic respiratory failure”
Submitted: July 31, 2023
Accepted: September 13, 2023
Published: September 28, 2023
Accepted: September 13, 2023
Abstract Views: 641
PDF: 94
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Dear Editor,
The recent study published by Ketan et al. provides emerging evidence on the expanding indications for high-flow nasal oxygen therapy in chronic obstructive pulmonary disease. The indications for hypoxemic respiratory failure are robust, and the indications for HFNO in hypercapnic respiratory failure are emerging...
Ketan PS, Kumar R, Mahendran AJ, et al. Post extubation high flow nasal cannula oxygen therapy versus non-invasive ventilation in chronic obstructive pulmonary disease with hypercapnic respiratory failure. Monaldi Arch Chest Dis 2023;94:2576.
Oczkowski S, Ergan B, Bos L, et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. Eur Respir J 2022;59:2101574.
Pierucci P, Crimi C, Carlucci A, et al. REINVENT: ERS International survey on REstrictive thoracic diseases IN long term home noninvasive VENTilation. ERJ Open Res 2021;7:00911-2020.
Hernández G, Vaquero C, Colinas L, et al. Effect of postextubation high-flow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients: a randomized clinical trial. JAMA 2016;316:1565-74.
Thille AW, Muller G, Gacouin A, et al. Effect of postextubation high-flow nasal oxygen with noninvasive ventilation vs high-flow nasal oxygen alone on reintubation among patients at high risk of extubation failure: a randomized clinical trial. JAMA 2019;322:1465-75.
Tan D, Walline JH, Ling B, et al. High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial. Crit Care 2020;24:489.
Jing G, Li J, Hao D, et al. Comparison of high flow nasal cannula with noninvasive ventilation in chronic obstructive pulmonary disease patients with hypercapnia in preventing postextubation respiratory failure: A pilot randomized controlled trial. Res Nurs Health 2019;42:217-25.
Du Y, Zhang H, Ma Z, et al. High-flow nasal oxygen versus noninvasive ventilation in acute exacerbation of chronic obstructive pulmonary disease patients: a meta-analysis of randomized controlled trials. Can Respir J 2023;2023:7707010.
Mittal A, Varshney M, Rathi V, Ish P. High flow nasal cannula in acute hypercapnic exacerbation of chronic obstructive pulmonary disease: an emerging utility. Monaldi Arch Chest Dis 2020;90:1158.
Thille AW, Coudroy R, Nay MA, et al. Non-invasive ventilation alternating with high-flow nasal oxygen versus high-flow nasal oxygen alone after extubation in COPD patients: a post hoc analysis of a randomized controlled trial. Ann Intensive Care 2021;11:30.
How to Cite
Rathi, Vidushi. 2023. “Comments on ‘Post-Extubation High-Flow Nasal Cannula Oxygen Therapy <i>versus< i> Non-Invasive Ventilation in Chronic Obstructive Pulmonary Disease With Hypercapnic Respiratory failure’”. Monaldi Archives for Chest Disease 94 (3). https://doi.org/10.4081/monaldi.2023.2737.
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
